Abstract | BACKGROUND: The ubiquitin- proteasome system has become a promising novel molecular target in cancer due to its critical role in cellular protein degradation, its interaction with cell cycle and apoptosis regulation and its unique mechanism of action. OBJECTIVE: METHODS: RESULTS/CONCLUSION:
|
Authors | Jan Sterz, Ivana von Metzler, Jens-Claus Hahne, Britta Lamottke, Jessica Rademacher, Ulrike Heider, Evangelos Terpos, Orhan Sezer |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 17
Issue 6
Pg. 879-95
(Jun 2008)
ISSN: 1744-7658 [Electronic] England |
PMID | 18491989
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Boronic Acids
- Neoplasm Proteins
- Protease Inhibitors
- Proteasome Inhibitors
- Pyrazines
- Ubiquitin
- Bortezomib
|
Topics |
- Antineoplastic Agents
(adverse effects, pharmacology, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Boronic Acids
(administration & dosage, adverse effects, pharmacology, therapeutic use)
- Bortezomib
- Cell Line, Tumor
(drug effects)
- Clinical Trials as Topic
(statistics & numerical data)
- Combined Modality Therapy
- Drug Design
- Drug Screening Assays, Antitumor
- Hematologic Neoplasms
(drug therapy, metabolism, surgery)
- Hematopoietic Stem Cell Transplantation
- Humans
- Neoplasm Proteins
(antagonists & inhibitors, metabolism)
- Neoplasms
(drug therapy, enzymology)
- Protease Inhibitors
(administration & dosage, adverse effects, pharmacology, therapeutic use)
- Proteasome Inhibitors
- Protein Processing, Post-Translational
(drug effects, physiology)
- Pyrazines
(administration & dosage, adverse effects, pharmacology, therapeutic use)
- Salvage Therapy
- Ubiquitin
(physiology)
- Ubiquitination
|